PRINUTA 20 ml (Trastuzumab 440 mg)

• HER2-positive metastatic breast cancer
  
  
• Early-stage HER2-positive breast cancer (adjuvant use)
  
  
• HER2-positive metastatic gastric cancer

The product is administered via intravenous infusion. The lyophilized powder should be reconstituted with the provided solvent prior to use. Dosage and treatment schedules are determined by an oncologist based on patient weight and clinical condition. The first infusion is given slowly with close monitoring.

Contraindications:

• Hypersensitivity to trastuzumab or murine proteins
  
  
• Severe heart failure
  
  
• Concurrent anthracycline therapy without cardiac monitoring
  
  
• Pregnancy and lactation
  
  
• Paediatric use under 18 years
  
  

Side effects:

• Fever, chills, fatigue during infusion
  
  
• Diarrhoea, nausea, abdominal pain
  
  
• Upper respiratory infections
  
  
• Heart failure, decreased ejection fraction
  
  
• Allergic or anaphylactic reactions
  
  
• Skin rash, itching
  
  
• Elevated liver enzymes